The autoantibody binds to a very specific functional domain of CFH in SCR 19, blocks binding of CFH to C3b on the tumour cell, and thus promotes complement‐dependent tumour cell lysis with subsequent inhibition of tumour growth (Bushey et al., 2016). The gene discussed is CFH; the disease is neoplasm.